GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of how much of what we believe about endpoint actually comes from SURMOUNT threads — 45 comments in the full submission. View in context.
1.6k
c/trialwatch·submitted 2 years ago by u/hsa_math

how much of what we believe about endpoint actually comes from SURMOUNT threads

Readoutbranch of 8 comments

how much of what we believe about endpoint actually comes from SURMOUNT threads. I am not trying to be the "source?" guy. I would just like a source. How to read one of these papers in fifteen minutes, in the order that actually helps. Start with the registered protocol and check the primary endpoint against what is…

Read the full submission and all 45 comments →

This branch

8 comments, started 2 years ago
u/laila_almeida90 points·2 years ago

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

replysharereportpermalink
u/hsa_mathOP34 points·2 years ago

the appendix is where the interesting tables live

replysharereportpermalink
u/nayeli_fonseca68 points·2 years ago

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

replysharereportpermalink
u/hsa_mathOP43 points·2 years ago

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

replysharereportpermalink
[removed]31 points·2 years ago

[removed by moderator]

replysharereportpermalink
u/hsa_math26 points·2 years ago

The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.

replysharereportpermalink
u/paper_trail_paulavetting6 points·2 years ago

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/rohan_cardoso39 points·2 years ago

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.